OBJECTIVE: To define the genetic landscape of amyotrophic lateral sclerosis (ALS) and assess the contribution of possible oligogenic inheritance, we aimed to comprehensively sequence 17 known ALS genes in 391 ALS patients from the United States. METHODS: Targeted pooled-sample sequencing was used to identify variants in 17 ALS genes. Fragment size analysis was used to define ATXN2 and C9ORF72 expansion sizes. Genotype-phenotype correlations were made with individual variants and total burden of variants. Rare variant associations for risk of ALS were investigated at both the single variant and gene level. RESULTS: A total of 64.3% of familial and 27.8% of sporadic subjects carried potentially pathogenic novel or rare coding variants identified by sequencing or an expanded repeat in C9ORF72 or ATXN2; 3.8% of subjects had variants in >1 ALS gene, and these individuals had disease onset 10 years earlier (p = 0.0046) than subjects with variants in a single gene. The number of potentially pathogenic coding variants did not influence disease duration or site of onset. INTERPRETATION: Rare and potentially pathogenic variants in known ALS genes are present in >25% of apparently sporadic and 64% of familial patients, significantly higher than previous reports using less comprehensive sequencing approaches. A significant number of subjects carried variants in >1 gene, which influenced the age of symptom onset and supports oligogenic inheritance as relevant to disease pathogenesis.
OBJECTIVE: To define the genetic landscape of amyotrophic lateral sclerosis (ALS) and assess the contribution of possible oligogenic inheritance, we aimed to comprehensively sequence 17 known ALS genes in 391 ALSpatients from the United States. METHODS: Targeted pooled-sample sequencing was used to identify variants in 17 ALS genes. Fragment size analysis was used to define ATXN2 and C9ORF72 expansion sizes. Genotype-phenotype correlations were made with individual variants and total burden of variants. Rare variant associations for risk of ALS were investigated at both the single variant and gene level. RESULTS: A total of 64.3% of familial and 27.8% of sporadic subjects carried potentially pathogenic novel or rare coding variants identified by sequencing or an expanded repeat in C9ORF72 or ATXN2; 3.8% of subjects had variants in >1 ALS gene, and these individuals had disease onset 10 years earlier (p = 0.0046) than subjects with variants in a single gene. The number of potentially pathogenic coding variants did not influence disease duration or site of onset. INTERPRETATION: Rare and potentially pathogenic variants in known ALS genes are present in >25% of apparently sporadic and 64% of familial patients, significantly higher than previous reports using less comprehensive sequencing approaches. A significant number of subjects carried variants in >1 gene, which influenced the age of symptom onset and supports oligogenic inheritance as relevant to disease pathogenesis.
Authors: Marka van Blitterswijk; Michael A van Es; Eric A M Hennekam; Dennis Dooijes; Wouter van Rheenen; Jelena Medic; Pierre R Bourque; Helenius J Schelhaas; Anneke J van der Kooi; Marianne de Visser; Paul I W de Bakker; Jan H Veldink; Leonard H van den Berg Journal: Hum Mol Genet Date: 2012-05-29 Impact factor: 6.150
Authors: Amelia Conte; Serena Lattante; Marco Luigetti; Alessandra Del Grande; Angela Romano; Alessandro Marcaccio; Giuseppe Marangi; Paolo Maria Rossini; Giovanni Neri; Marcella Zollino; Mario Sabatelli Journal: J Neurol Neurosurg Psychiatry Date: 2012-07-08 Impact factor: 10.154
Authors: Chi-Hong Wu; Claudia Fallini; Nicola Ticozzi; Pamela J Keagle; Peter C Sapp; Katarzyna Piotrowska; Patrick Lowe; Max Koppers; Diane McKenna-Yasek; Desiree M Baron; Jason E Kost; Paloma Gonzalez-Perez; Andrew D Fox; Jenni Adams; Franco Taroni; Cinzia Tiloca; Ashley Lyn Leclerc; Shawn C Chafe; Dev Mangroo; Melissa J Moore; Jill A Zitzewitz; Zuo-Shang Xu; Leonard H van den Berg; Jonathan D Glass; Gabriele Siciliano; Elizabeth T Cirulli; David B Goldstein; Francois Salachas; Vincent Meininger; Wilfried Rossoll; Antonia Ratti; Cinzia Gellera; Daryl A Bosco; Gary J Bassell; Vincenzo Silani; Vivian E Drory; Robert H Brown; John E Landers Journal: Nature Date: 2012-08-23 Impact factor: 49.962
Authors: Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean Journal: Nature Date: 2012-11-01 Impact factor: 49.962
Authors: Cyril Pottier; Kevin F Bieniek; NiCole Finch; Maartje van de Vorst; Matt Baker; Ralph Perkersen; Patricia Brown; Thomas Ravenscroft; Marka van Blitterswijk; Alexandra M Nicholson; Michael DeTure; David S Knopman; Keith A Josephs; Joseph E Parisi; Ronald C Petersen; Kevin B Boylan; Bradley F Boeve; Neill R Graff-Radford; Joris A Veltman; Christian Gilissen; Melissa E Murray; Dennis W Dickson; Rosa Rademakers Journal: Acta Neuropathol Date: 2015-05-06 Impact factor: 17.088
Authors: Laurie A Robak; Iris E Jansen; Jeroen van Rooij; André G Uitterlinden; Robert Kraaij; Joseph Jankovic; Peter Heutink; Joshua M Shulman Journal: Brain Date: 2017-12-01 Impact factor: 13.501